It is possible that, akin to HER2 inhibitors, the level of amplification of FGFR1 and the level of protein expression will need to be taken into consideration in the targeted development of FGFR inhibitors for the therapy of 8p11.23 amplified breast cancers and other types of cancer with the amplicon. This evidence concerns the gene ERBB2 and breast carcinoma.